{"slideshow_credits": null, "snippet": "Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study.", "abstract": "Food and Drug Administration approves Opdivo, first immune-based treatment for lung cancer, produced by Bristol-Myers Squibb; drug is also known as nivolumab and could be used instead of conventional chemotherapy for some patients.", "section_name": "Business Day", "print_page": "10", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/03/05/business/lung-cancer-treatment-using-immune-system-wins-fda-approval.html", "lead_paragraph": "Opdivo, from Bristol-Myers Squibb, which harnesses the body\u2019s own immune system to attack tumors, was approved after strong results in a study.", "headline": {"main": "Lung Cancer Treatment Using Immune System Wins F.D.A. Approval", "print_headline": "F.D.A. Backs a Lung Cancer Therapy"}, "_id": "54f7db1c38f0d8579fff618c", "word_count": "627", "multimedia": [], "pub_date": "2015-03-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Lung Cancer", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Melanomas", "is_major": "N", "rank": "4"}, {"name": "organizations", "value": "Food and Drug Administration", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Merck & Company Inc", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}